Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to cut relapse in rare lymphoma

NCT ID NCT07450040

Disease control Sponsor: Eye & ENT Hospital of Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug tislelizumab to standard chemotherapy and radiation can improve outcomes for people with early-stage NK/T-cell lymphoma, a rare blood cancer. About 60 adults aged 18 to 70 will receive the combination treatment. The goal is to see if this approach increases the number of patients whose tumors shrink significantly and helps prevent the cancer from coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study was conducted in patients with primary stage I-II NK/ T-cell lymphoma (subjects must have a measurable tumor lesion at baseline).

Ages

18 to 70 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of NK/T cell lymphoma . * Stage I/II patients . * Age 18-70. * ECOG score 0-2 points. * Sign informed consent. * Voluntary compliance with research protocols, follow-up plans, laboratory and auxiliary examinations. Exclusion Criteria: * Patients with HCV or HIV infection and HBV infection receiving antiviral therapy at the same time are not excluded. * Complicated with severe infection requires ICU treatment. * There are serious complications such as hemophagic syndrome, DIC, etc. * Functional impairment of major organs. * A history of autoimmune disease. * Pregnant or lactating women. * Patients with a history of psychotropic drug abuse who cannot abstain or have mental disorders. * Patients who are known to be allergic to drugs used in chemotherapy regimens. * Patients with other tumors requiring surgery or chemotherapy within 6 months. * Patients who have participated in other clinical trials within 4 weeks prior to the trial; * Patients who are taking other investigational drugs. * Patients with severe allergic history or allergic constitution. * The target lesion has received radiation therapy or surgery (except biopsy); * Previously used chemotherapy, immunotherapy or biological targeted therapy for the primary tumor.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extranodal NK/T cell lymphoma, nasal type are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

extranodal nasal NK/T cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ORR OS PFS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • EENT hospital of Fudan University

    Shanghai, China, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.